Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050

Fertility and Sterility

Volumn 87, Issue 1, 2007, Pages 127-135

  Shushan, Asher ^a   Ben Bassat, Hannah ^a   Mishani, Eyal ^a   Laufer, Neri ^a   Klein, Benjamine Y ^a   Rojansky, Nathan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

genistein; Leiomyoma; protein tyrosine kinase (PTK) inhibitors; signal transduction therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; GENISTEIN; N [4 [(3,4 DICHLORO 6 FLUOROPHENYL)AMINO]QUINAZOLINE 6 YL] 2 CHLOROACETAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; TKS 050; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BIOACCUMULATION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MITOSIS INHIBITION; MUSCLE CELL; PHARMACOLOGICAL BLOCKING; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UTERUS MYOMA;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENISTEIN; HUMANS; LEIOMYOMA; PROTEIN-TYROSINE KINASES; QUINAZOLINES; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 33845742037     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.05.056     Document Type: Article

References (29)

1. Stewart E.A. Uterine fibroids. Lancet 357 (2001) 293-298
2. Farquhar C.M., and Steiner C.A. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 99 (2002) 229-234
3. Baird D.D., Dunson D.B., Hill M.C., Cousins D., and Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188 (2003) 100-107
4. Shozu M., Murakami K., and Inoue M. Aromatase and leiomyoma of the uterus. Semin Reprod Med 22 (2004) 51-60
5. Sozen I., and Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 78 (2002) 1-12
6. Flake G.P., Andersen J., and Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111 (2003) 1037-1054
7. Arslan A.A., Gold L.I., Mital K., Suen T.C., Belitskaya-Levy I., Tang M.S., et al. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 20 (2005) 852-863
8. Hofmann G.E., Rao C.V., Barrows G.H., Schultz G.S., and Sanfilippo J.S. Binding sites for epidermal growth factor in human uterine tissues and leiomyomas. J Clin Endocrinol Metab 58 (1984) 880-884
9. Shimomura Y., Matsuo H., Samoto T., and Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83 (1998) 2192-2198
10. Shushan A., Rojansky N., Laufer N., Klein B.Y., Shlomai Z., Levitzki R., et al. The AG1478 tyrosine kinase inhibitor is an effective supressor of leiomyoma cell growth. Hum Reprod 19 (2004) 1957-1967
11. Gazit A., Chen J., App H., McMahon G., Hirth P., Chen I., et al. Tyrphostins IV-highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg Med Chem 4 (1996) 1203-1207
12. Ben-Bassat H., Rosenbaum-Mitrani S., Hartzstark Z., Shlomai Z., Kleinberger-Doron N., Gazit A., et al. Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. Cancer Res 57 (1997) 3741-3750
13. Matsuo H., Kurachi O., Shimomura Y., Samoto T., and Maruo T. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 57 (1999) 49-58
14. Mishani E., Abourbeh G., Jacobson O., Dissoki S., Ben Daniel R., Rozen Y., et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 48 (2005) 5337-5348
15. Matsuo H., Maruo T., and Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82 (1997) 293-299
16. Wei J.J., Chiriboga L., Arslan A.A., Melamed J., Yee H., and Mittal K. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod 21 (2006) 57-67
17. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 6 (1992) 3275-3282
18. Ben-Bassat H., and Klein B.Y. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 6 (2000) 933-942
19. Powell T.J., Ben-Bassat H., Klein B.Y., Chen H., Shenoy N., McCollough J., et al. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 141 (1999) 802-810
20. Nagane M., Narita Y., Mishima K., Levitzki A., Burgess A.W., Cavenee W.K., et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95 (2001) 472-479
21. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 (2002) 200-207
22. Zhou Y., and Brattain M.G. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. Cancer Res 65 (2005) 5848-5856
23. Arbel R., Rojansky N., Klein B.Y., Levitzki R., Hartzstark Z., Laufer N., et al. Inhibitors that target protein kinases for the treatment of ovarian carcinoma. Am J Obstet Gynecol 188 (2003) 1283-1290
24. Li Y., Upadhyay S., Bhuiyan M., and Sarkar F.H. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18 (1999) 3166-3172
25. Marks L.S., Kojima M., Demarzo A., Heber D., Bostwick D.G., Qian J., et al. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology 64 (2004) 765-771
26. Zhou J.R., Mukherjee P., Gugger E.T., Tanaka T., Blackburn G.L., and Clinton S.K. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 15 (1998) 5231-5238 58
27. Li C., Teng R.H., Tsai Y.C., Ke H.S., Huang J.Y., Chen C.C., et al. H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells. Br J Cancer 92 (2005) 80-88
28. Haura E.B., Zheng Z., Song L., Cantor A., and Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11 (2005) 8288-8294
29. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 36 (2003) 462-469